Dopamine agonist therapy for neglect in humans.
Lesions of ascending dopaminergic pathways induce neglect in animals. Apomorphine, a dopamine receptor agonist, decreases the magnitude of neglect in rats with cortical lesions. We treated two patients with 15 mg of bromocriptine daily for 3 to 4 weeks, one with chronic (longer than 6 months) and one with relatively more acute disabling neglect. Tests for neglect that significantly improved on therapy and worsened after its withdrawal included line, letter, and geometric figure cancellation tasks. Neither patient noted any untoward effects. Based on this open trial of dopamine agonist therapy in humans with neglect, larger controlled studies may be warranted.
Fleet
W S
WS
Department of Neurology, University of Florida, Gainesville 32610.
Valenstein
E
E
Watson
R T
RT
Heilman
K M
KM
D000328:Adult; D001921:Brain / Q000000981:diagnostic imaging; D001971:Bromocriptine / Q000627:therapeutic use*; D002544:Cerebral Infarction / Q000188:drug therapy* / Q000503:physiopathology / Q000523:psychology; D005260:Female; D006801:Humans; D007858:Learning / Q000187:drug effects; D008297:Male; D008875:Middle Aged; D011954:Receptors, Dopamine / Q000187:drug effects / Q000502:physiology*; D014057:Tomography, X-Ray Computed
D011954:Receptors, Dopamine; D001971:Bromocriptine